Ioannis Zerdes

Clinical Fellow in Medical Oncology @KarolinskaUnsju & Associate Professor at @karolinskainst Karolinska Comprehensive Cancer Center. Chair Y-ECI @EORTC_BCG

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Invest where impact begins: recommendations from #BreastCancer Research Foundation Early Career Investigator Working Group now out in @Nature_NPJ.
🔓https://t.co/VBNvO54cfT
@nlinmd @judygarber5 @YAbdouMD @MariyaRozenblit @darioT_ @io_zerdes @DrLisaCarey @DorrayaElAshry @JuliaFoldiMD @christeeny513 @LarryNortonMD @MammaMiaMagazin @shanestecklein @HollyTovey @DrEricWiner @awolff @Seamusoreilly18

[OncoDailyBreast @OncoDailyBreast]

🧬 PREDIX LumB did not deliver a clear neoadjuvant win for palbociclib over chemotherapy, but that is not the most important finding.

In this randomized phase II trial in ER-positive/HER2-negative breast cancer, radiologic response at 12 weeks was 59% with paclitaxel versus 45% with palbociclib plus endocrine therapy, narrowly missing statistical significance.

📊 On the surface, that looks like another setback for neoadjuvant CDK4/6 inhibition.

But the real story may be deeper. 🔍

Researchers developed CDKPredX, a 31-gene transcriptomic signature that identified tumors resistant to chemotherapy yet still responsive to palbociclib plus endocrine therapy. Even more importantly, that signal was independently validated in CORALLEEN.

✨ That means PREDIX LumB may not be the trial that changes practice today.
✨ It may be the trial that shows how practice could change tomorrow.

In ER+/HER2- breast cancer, the future may not be about giving the same neoadjuvant treatment to everyone.
It may be about identifying which tumor truly needs chemotherapy, and which one may not. 🎯

Read our full breakdown on @OncoDailyBreast

https://t.co/504bCRPETf

@io_zerdes @carljhartman

#BreastCancer #ERPositive #HER2Negative #Palbociclib #CDK46 #PREDIXLumB #CDKPredX #PrecisionOncology #BreastOncology #OncoDailyBreast

[EORTC Breast Cancer Group @EORTC_BCG]

⏳Starting tomorrow! Welcome to EBCC @BreastEuropean in Barcelona🇪🇸, one of Europe’s largest multidisciplinary #breastcancer meetings
Join the @EORTC Breast Cancer Group Session on career development, mentorship and research collaboration
🗓️Mar 26 |⏰ 08:30–09:30 | 📍Room 122

[Cancer Core Europe (CCE) @CancerCoreEU]

Ioannis Zerdes, professor at @karolinskainst & #TRYTRACer, shares his reflections from the second in-person meeting: a well-designed program for early-career researchers.
🚀 Next stop: @IstTumori
🔗https://t.co/sCYbnns5eN
@GustaveRoussy @NKI_nl  @CRUKCamCentre @NCT_HD @DKFZ @VHIO

[EORTC @EORTC]

👏Yesterday marked the end of the EORTC ECI Programme for Early Career Investigators: 9 sessions, 40 ECIs!

EORTC fosters young doctors in clinical & translational cancer research.

Interested in becoming an ECI?

🔗 Learn more on our website: https://t.co/DplKeOgQcm

[Cancer Core Europe (CCE) @CancerCoreEU]

🚀 Kicking off the 2nd #CCETRYTRAC face-to-face meeting — this time at @NCT_HD, Germany!

💡 Excited for three days of learning, exchange, and networking.

@VHIO @DKFZ @IstTumori @karolinskainst @NKI_nl @GustaveRoussy @CRUKCamCentre

[EORTC Breast Cancer Group @EORTC_BCG]

⌛️Only a few days left to submit your abstract for #EBCC15 in Barcelona. Join us in driving progress in #BreastCancer research by sharing your latest data, innovative ideas and impactful findings
🗓️Submission deadline: 3 November
🔗https://t.co/GrYS1M2CZA
@EORTC @OncoAlert #bcsm

[Paolo Tarantino @PTarantinoMD]

Discussion by @TFoukakis: impressively similar benefit of low-dose pembro in KN522 and PLANeT- yet the latter was a small phase 2 trial, hypothesis generating rather than practice changing. MANY pending questions in the field of neoadjuvant IO for TNBC. A lot of work needed.

[EORTC @EORTC]

📢 Registration is now open for EBCC-15!
📍 Barcelona | 25–27 March 2026
Join us in shaping the future of multidisciplinary breast cancer care
https://t.co/z49ddfWNfv
#EBCC15 #BreastCancer #Oncology #BCSM @OncoAlert @EORTC_BCG @EuropaDonnaEUR

[Seamus O’Reilly MD PhD @Seamusoreilly18]

🤔How can we ⬆️ access to innovation for ALL 🌎🌍🌏patients with #breastcancer

@BIGxResearch 📝 @Nature_NPJ
Free access link 👉https://t.co/5qrJFoqRv9
Successes of the past ✅
Pitfalls of the present ✅
Solutions for the future eg @Path4Young✅
🙏to co-✍️& funders 💶

[Cancer Core Europe (CCE) @CancerCoreEU]

Meet more of our #CCESumSchool25 speakers!

🤖 This group of experts will explore the Tumor Microenvironment (TME) and advances in #AI-driven and Computational Oncology

@jnkath @nlbigas @Elsa2Bernard @AndriPapakonst

[Dario Trapani @darioT_]

Such a unique opportunity to share #ideas and perspectives on the present and future of #bcsm , a sincerest gratitude to #BIG #NCTN & @BCRFcure for the support and the incredible chairs @nlinmd & @Seamusoreilly18 !!

[Ioannis Zerdes @io_zerdes]

Honored to present at the @BIGxResearch - @theNCI NCTN Annual Meeting in Chicago 🇺🇸, marking 20 years of global collaboration in #breastcancerresearch
Many thanks to @BCRFcure & Drs @Seamusoreilly18 @nlinmd @darioT_ @YAbdouMD @MariyaRozenblit for an inspiring session! @OncoAlert

[Seamus O’Reilly MD PhD @Seamusoreilly18]

👏👏👏Superb presentation by Drs Abdou, Trapani, Zerdes & Rozenblit @BIGxResearch @theNCI NCTN mtg funded by @BCRFcure

Eloquent outline of how we can help them impact patient care 👇

[Nancy Lin, MD @nlinmd]

“Invest where the impact begins”:
Tremendous session at the BIG-NCTN annual meeting laying out a roadmap for how to nurture and support the next generation of cancer researchers. @darioT_ @YAbdouMD @MariyaRozenblit @io_zerdes @Seamusoreilly18 @BIGxResearch

[Yara Abdou, MD, MSCR @YAbdouMD]

Honored to present at the BIG-NCTN annual meeting to voice the needs of early-career investigators along with colleagues!

The future of clinical trials depends on equity, mentorship, and structural support—and that begins with investing in those just starting out.

Thanks to @Seamusoreilly18 and @nlinmd for the opportunity.

#InvestWhereImpactBegins #EarlyCareerInvestigators
@BCRFcure

[Ioannis Zerdes @io_zerdes]

Thank you @PTarantinoMD , great having you for a visit at Karolinska. Looking forward to future collaborations! @TFoukakis
@karolinskainst @KarolinskaUnsju @CancerResKI

[Paolo Tarantino @PTarantinoMD]

So grateful with the @karolinskainst Breast Onc team for the warm welcome and tour of this impressive institution. The seamless way you bridge clinical and translational oncology is remarkable. Looking forward to many potential collaborations to end breast cancer!

[Ioannis Zerdes @io_zerdes]

🎉 Honoured to celebrate #ClinicalTrialsDay as part of the @EORTC Early Career Investigator network — a dynamic community driving progress in cancer research.
🔬 Clinical trials are key to advancing patient care.
🔗 https://t.co/t9y90EyDck
#EORTC #CancerResearch #ClinicalResearch

[EORTC @EORTC]

On #ClinicalTrialsDay, meet the next generation driving #CancerResearch forward.

In this video, @io_zerdes, @JLehmann_IBK, and @A_Cammarota_ share what it means to be part of the EORTC Early Career Investigator community.

Learn more: https://t.co/DqMWQGxiYm

[Ioannis Zerdes @io_zerdes]

Back from an inspiring #ESMOBreast25 in Munich!
Great days of science, collaboration & interaction with colleagues
Proud of the Karolinska Breast Oncology Group — 1 mini-oral & 12 posters showcasing exciting new research. Glad to be part of the @myESMO community! #bcsm @OncoAlert

[Elisa Agostinetto @ElisaAgostinett]

At #ESMOBreast25 @TFoukakis presents CDKPredX, a new metagene-based (ER, proliferation, immune) predictor of response to neoadjuvant CDK4/6i + ET vs CT

Prospective validation is planned 🔜

@OncoAlert